On the stock market since 2015, it operates in the world of health and science. It has 66 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 73% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $37.2M. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 722% — still a thick cushion, though costs have been eating into it lately.
The average analyst price target is $12.00 — 163% above today’s price.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 9/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 11/100. For a turnaround signal, the stock first needs to close the gap with the market.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 13/100.
On our five-subject report card, MCRB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MCRB is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (9/100) says the stock isn’t cheap.